Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 14.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 148,200 shares, a decrease of 14.8% from the November 15th total of 173,900 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 90,200 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is currently owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Trading Down 4.0 %

BCLI traded down $0.06 on Friday, reaching $1.45. The stock had a trading volume of 46,458 shares, compared to its average volume of 61,048. The business’s 50-day moving average price is $1.71 and its two-hundred day moving average price is $3.85. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89. The company has a market cap of $8.27 million, a P/E ratio of -0.30 and a beta of 0.36.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.